|
 MedVital, a medtech company focused on skin repair and regeneration, has raised Rs. 18 crore in a growth funding round led by Alkemi Growth Capital, with participation from Dr Sanjay Arora, Shubhan Ventures, and existing investors. This follows the company’s previous round led by 4point0 Health Ventures and entrepreneur investors, signalling continued conviction as MedVital scales its presence across hospitals in India.
The funding will support expansion, accelerate product development, and build proprietary capabilities across devices, biomaterials, and biologics, while strengthening supply chain efficiency and unit economics.
Founded in 2024, MedVital is building medical technologies at the intersection of advanced wound care, regenerative aesthetics, and chronic skin conditions, where clinical need remains large and underserved. Skin and hair conditions, including wounds, ageing, and chronic dermatological issues, are fundamentally linked to gaps in repair and regeneration. MedVital addresses this making innovative evidence based technologies more accessible and tailored to specific clinical used case scenario across these segments.
The company currently operates in advanced wound care through its NoWound portfolio, which includes Negative Pressure Wound Therapy (NPWT) and a chitosan-based liquid bandage designed for hospital settings. Despite the scale of need, adoption of advanced wound care therapies in India remains at an early stage, creating significant opportunity. MedVital has already established early clinical traction with adoption across 200+ leading corporate and public healthcare institutions, supported by strong repeat usage.
In parallel, the company has launched Elyara, a portfolio of products in regenerative medical aesthetics focused on non-invasive skin and hair restoration, leveraging peptide-led signalling and regenerative pathways.
Commenting on the fundraise, Dr Varun Gupta, co-founder, MedVital, said, “Skin, the body’s largest organ, is increasingly impacted by ageing, diabetes and a growing burden of chronic dermatolgical conditions-yet access to innovative, evidence-based technologies remain limited. We’re building clinical driven technologies spanning biomaterials, device based systems, biologics across wound care, aesthetics, and chronic dermatology”.
Alka Goel, founder and managing partner, Alkemi Growth Capital, said, “MedVital is addressing a large and growing clinical need with a platform-led approach. The team has demonstrated early hospital adoption, strong product depth, and disciplined execution, positioning the company to build a globally relevant regenerative care business from India.”
Dr Sanjay Arora, founding partner, Shubhan Ventures, added, “The company’s emphasis on product quality, regulatory readiness, and long-term capability building stands out. These are critical foundations for sustainable scale in healthcare.”
Going forward, MedVital will expand its footprint across hospitals and healthcare institutions while continuing to invest in clinical education and evidence-led adoption. With a growing wound care portfolio and an evolving regenerative aesthetics pipeline, the company is focused on building a medtech platform anchored in proprietary products and consistent clinical outcomes.
MedVital is a medtech company focused on advancing repair and regeneration across wound care and regenerative medical aesthetics. Founded in 2024, the company develops clinically driven medical technologies spanning devices, biomaterials, and integrated care protocols, with a growing footprint across hospitals in India.
|